You are here: Industry Insights > SARS-CoV-2

News List

To Win the Fight against COVID-19 in the Future, How To Make a Breakthrough in the R&D of New Drug? PharmaSources/Professor in medical field
March 21, 2022
Recently, with the continuous evolution and spread of Novel Coronavirus variant (including Delta-related variant viruses) all over the world, the mortality rate in some areas has a tendency to increase.
Increased COVID-19 testing triggers demand for kit reagents Shem Oirere
February 22, 2022
The emerging new mutations of COVID-19 is fueling the global drive for mass testing hence increasing demand for reagents for both testing kits and vaccine production especially in low- and middle-income countries.
Will EXO-CD24, the New Drug from Israeli, Bring COVID-19 to an End? PharmaSources/Big Cat in the Pharma Industry
August 25, 2021
Recently, the issue that Israeli medical staff obtained a new drug named EXO-CD24 with remarkable curative effect on COVID-19 infection are making a lot of headlines on domestic media.
The Bulky Size of SARS-CoV-2 Might Make the Antibodies of Vaccine Ineffective PharmaSources/Professor in Medical Field
June 16, 2021
Coronavirus is a positive-sense single-stranded RNA virus with a thick envelope, which has the largest genetic material among all the RNA viruses, and it is a key pathogen for many diseases of domestic animals, pets and human.
Neutralizing Antibodies, the “Specific Drugs” against SARS-CoV-2 PharmaSources/Yefenghong
March 04, 2021
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has developed into a global pandemic and become a serious public health and socioeconomic burden, and thus there is an urgent need for effective means of control.
Discovering Biotechnology: Developments in COVID-19 Diagnostic tests Deborah Seah
November 09, 2020
Diagnostic tests by definition are any method used to obtain information of a patient’s clinical condition for healthcare professionals to make an informed clinical decision.
Junshi and Eli Lilly have reached a USD 255 million COVID-19 Virus Antibody Authorization Deal CPhI.CN
May 06, 2020
On May 4, Junshi Biosciences and Eli Lilly Pharma announced that the two parties have reached an agreement to jointly develop and commercialize SARS-CoV-2 neutralizing antibodies against new coronary pneumonia caused by the new SARS-CoV-2 coronavirus.
IgY antibody technology against SARS-CoV-2 unveiled PharmaSources.com
February 18, 2022
An IgY neutralizing antibody, which is claimed to inhibit the activity of SARS-CoV-2, the novel coronavirus that causes COVID-19, by over 99 percent, was launched in Shenzhen on Monday, according to Shenzhen Special Zone Daily.
Novel antibody helps block COVID transmission in cells, finds study ExpressPharma
February 15, 2022
The antibody, FuG1, targets the enzyme furin, which the virus uses for its efficient chain of infections in human cells.
Celartics Biopharma announces a new generation mRNA vaccine against COVID-19 FirstWordPharma
February 14, 2022
Celartics Biopharma today announced that they have achieved major milestones and encouraging results in developing a new generation of mRNA vaccine, CA-R03, designed to prevent infection from SARS-COV-2 virus.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page